SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Nastech [NSTK] -Sm & Lrg Molecule Intranasal drug delivery -- Ignore unavailable to you. Want to Upgrade?


To: sjemmeri who wrote (62)12/4/2006 5:58:43 PM
From: IngotWeTrust  Respond to of 80
 
Thank you, Steven Emmerich for taking the time to post that Nastech update on the osteo-nasal spray collab., and contract re-jiggering!

Never thought in my lifetime I'd be able to have this as an option to sub-cue daily injections. What a hopeful development!

And God knows, I miss my friend, Ken Gammage, may he rest in peace. It will be a year this New Year's day 07, when he collected his heavenly reward. What a staunch believer, supporter and news guidance/pro's hand he lent to NSTK!

Ken, if yer listenin', buddy, we've come a loooooooong ways since the $5 per share days, eh?

G_T



To: sjemmeri who wrote (62)12/4/2006 6:05:53 PM
From: DewDiligence_on_SI  Read Replies (1) | Respond to of 80
 
The bottom line:

NSTK’s “tight junction” technology probably doesn’t work as well as the company says it does. In all these years, no drug using the technology has gotten very far into clinical development.